INDIANAPOLIS (WISH) — This week, it was reported that the FDA is reviewing the safety of two drugs, Clesrovimab (Enflonsia) and Nirsevimab (Beyfortus), both approved for the prevention of RSV in infants and toddlers.

What is RSV?

RSV, respiratory syncytial virus, is the most common cause of hospitalization of US infants under 1 year of age. It commonly affects infants, children and adults, leading to an upper respiratory tract infection and spreads via droplets from coughing to sneezing. For 20-30% of children infected with RSV, a lower respiratory tract infection (bronchiolitis or ...